SCHEMBL21664525

SCHEMBL21664525

O=C(CCC(=O)N1CCOCC1)ON1C(=O)CCC1=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.55
▸ TSHR P16473 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.54
▸ GLA P06280 1/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ GAA P10253 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ RAB9A P51151 3/20 0.44
▸ FKBP1A P62942 3/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ USP2 O75604 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197620 0.84 SMN1; SMN2 (0.44) POLBTSHRLMNAALDH1A1GLA
SCHEMBL19643061 0.80 GLA (0.49) LMNAALDH1A1GLASMN1; SMN2L3MBTL1
SCHEMBL43576 0.80 PSMB8 (0.35) TSHRLMNASMN1; SMN2
SCHEMBL19703782 0.79 NPC1 (0.53) LMNAALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL31522720 0.78 PSMB8 (0.34) LMNASMN1; SMN2
SCHEMBL16330527 0.77 ALDH1A1 (0.39) POLBTSHRLMNAALDH1A1GAA
SCHEMBL15263773 0.77 MGLL (0.48) POLBTSHRSMN1; SMN2GAAUSP2
SCHEMBL1243105 0.76 KDM4E (0.46) POLBTSHRLMNAALDH1A1SMN1; SMN2
SCHEMBL12092238 0.76 TACR1 (0.36) POLBTSHRLMNAALDH1A1HSD17B10
SCHEMBL32682848 0.76 DDB1 (0.49) LMNAALDH1A1SMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid SHIONOGI & CO., LTD. (JP) 2023-05-02 — — US disclosed
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid SHIONOGI & CO., LTD. (JP) 2023-05-02 — — US disclosed
US-20200384010-A1 COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID SHIONOGI & CO., LTD. (JP) 2020-12-10 — — US disclosed
EP-3603648-A1 COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID Shionogi & Co., Ltd (JP) 2020-02-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11638717-B2 Complex of nucleic acid medicine and multibranched lipid FABP1, POLRMT, SREBF1 POLB 69/4885TSHR 3187/4885LMNA 378/4885
US-20200384010-A1 COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID FABP1, POLRMT, SREBF1 POLB 69/4885TSHR 3187/4885LMNA 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback